Setd2 Inactivation Sensitizes Lung Adenocarcinoma to Inhibitors of Oxidative Respiration and MTORC1 Signaling

Overview

Journal Commun Biol

Specialty Biology

Date 2023 Mar 10

PMID 36899051

Authors

David M Walter

Amy C Gladstein

Katherine R Doerig

Ramakrishnan Natesan

Saravana G Baskaran

A Andrea Gudiel

Keren M Adler

Jonuelle O Acosta

Douglas C Wallace

Irfan A Asangani

David M Feldser

Affiliations

Soon will be listed here.

Abstract

SETD2 is a tumor suppressor that is frequently inactivated in several cancer types. The mechanisms through which SETD2 inactivation promotes cancer are unclear, and whether targetable vulnerabilities exist in these tumors is unknown. Here we identify heightened mTORC1-associated gene expression programs and functionally higher levels of oxidative metabolism and protein synthesis as prominent consequences of Setd2 inactivation in KRAS-driven mouse models of lung adenocarcinoma. Blocking oxidative respiration and mTORC1 signaling abrogates the high rates of tumor cell proliferation and tumor growth specifically in SETD2-deficient tumors. Our data nominate SETD2 deficiency as a functional marker of sensitivity to clinically actionable therapeutics targeting oxidative respiration and mTORC1 signaling.

Citing Articles

Identification and validation of an m5C-related lncRNA signature for predicting prognosis and immune response in clear cell renal cell carcinoma.

Ao S, Liang L, Peng L, Yang R, Chen Z, Deng T Discov Oncol. 2025; 16(1):227.

PMID: 39987537 PMC: 11847763. DOI: 10.1007/s12672-025-01987-5.

Histone H3 mutations and their impact on genome stability maintenance.

Caeiro L, Verdun R, Morey L Biochem Soc Trans. 2024; 52(5):2179-2191.

PMID: 39248209 PMC: 11580799. DOI: 10.1042/BST20240177.

Clinical, pathologic and molecular findings in 2 Rottweiler littermates with appendicular osteosarcoma.

Silver K, Mannheimer J, Saba C, Hendricks W, Wang G, Day K Res Sq. 2024; .

PMID: 38659878 PMC: 11042397. DOI: 10.21203/rs.3.rs-4223759/v1.

Tumor-suppressive functions of protein lysine methyltransferases.

Aziz N, Hong Y, Kim H, Kim J, Cho J Exp Mol Med. 2023; 55(12):2475-2497.

PMID: 38036730 PMC: 10766653. DOI: 10.1038/s12276-023-01117-7.

References

Jackson E, Olive K, Tuveson D, Bronson R, Crowley D, Brown M . The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005; 65(22):10280-8. DOI: 10.1158/0008-5472.CAN-05-2193. View

Nielsen J, Gejl K, Hey-Mogensen M, Holmberg H, Suetta C, Krustrup P . Plasticity in mitochondrial cristae density allows metabolic capacity modulation in human skeletal muscle. J Physiol. 2016; 595(9):2839-2847. PMC: 5407961. DOI: 10.1113/JP273040. View

Li J, Akbani R, Zhao W, Lu Y, Weinstein J, Mills G . Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. Cancer Res. 2017; 77(21):e51-e54. PMC: 5679242. DOI: 10.1158/0008-5472.CAN-17-0369. View

Liu J, Xu Y, Stoleru D, Salic A . Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin. Proc Natl Acad Sci U S A. 2011; 109(2):413-8. PMC: 3258597. DOI: 10.1073/pnas.1111561108. View

Carrer A, Wellen K . Metabolism and epigenetics: a link cancer cells exploit. Curr Opin Biotechnol. 2014; 34:23-9. PMC: 4721608. DOI: 10.1016/j.copbio.2014.11.012. View

Ye C, Tu B . Sink into the Epigenome: Histones as Repositories That Influence Cellular Metabolism. Trends Endocrinol Metab. 2018; 29(9):626-637. PMC: 6109460. DOI: 10.1016/j.tem.2018.06.002. View

DuPage M, Dooley A, Jacks T . Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc. 2009; 4(7):1064-72. PMC: 2757265. DOI: 10.1038/nprot.2009.95. View

Signer R, Magee J, Salic A, Morrison S . Haematopoietic stem cells require a highly regulated protein synthesis rate. Nature. 2014; 509(7498):49-54. PMC: 4015626. DOI: 10.1038/nature13035. View

Mitsudomi T, Steinberg S, Nau M, Carbone D, DAmico D, Bodner S . p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 1992; 7(1):171-80. View

10.

Kandoth C, McLellan M, Vandin F, Ye K, Niu B, Lu C . Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-339. PMC: 3927368. DOI: 10.1038/nature12634. View

11.

Schneider C, Rasband W, Eliceiri K . NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012; 9(7):671-5. PMC: 5554542. DOI: 10.1038/nmeth.2089. View

12.

Feldser D, Kostova K, Winslow M, Taylor S, Cashman C, Whittaker C . Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature. 2010; 468(7323):572-5. PMC: 3003305. DOI: 10.1038/nature09535. View

13.

Misbin R . The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care. 2004; 27(7):1791-3. DOI: 10.2337/diacare.27.7.1791. View

14.

Rogers Z, McFarland C, Winters I, Naranjo S, Chuang C, Petrov D . A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nat Methods. 2017; 14(7):737-742. PMC: 5495136. DOI: 10.1038/nmeth.4297. View

15.

Chen K, Liu J, Liu S, Xia M, Zhang X, Han D . Methyltransferase SETD2-Mediated Methylation of STAT1 Is Critical for Interferon Antiviral Activity. Cell. 2017; 170(3):492-506.e14. DOI: 10.1016/j.cell.2017.06.042. View

16.

Lee M, Hsu C, Wahlqvist M, Tsai H, Chang Y, Huang Y . Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011; 11:20. PMC: 3031263. DOI: 10.1186/1471-2407-11-20. View

17.

Shalem O, Sanjana N, Hartenian E, Shi X, Scott D, Mikkelson T . Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2013; 343(6166):84-87. PMC: 4089965. DOI: 10.1126/science.1247005. View

18.

Reid M, Dai Z, Locasale J . The impact of cellular metabolism on chromatin dynamics and epigenetics. Nat Cell Biol. 2017; 19(11):1298-1306. PMC: 5886854. DOI: 10.1038/ncb3629. View

19.

Currie C, Poole C, Jenkins-Jones S, Gale E, Johnson J, Morgan C . Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012; 35(2):299-304. PMC: 3263862. DOI: 10.2337/dc11-1313. View

20.

Park I, Powell R, Tripathi D, Dere R, Ho T, Blasius T . Dual Chromatin and Cytoskeletal Remodeling by SETD2. Cell. 2016; 166(4):950-962. PMC: 5101839. DOI: 10.1016/j.cell.2016.07.005. View